Therapy Detail

Therapy Name Bevacizumab + Carotuximab
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Bevacizumab Avastin VEGF Antibody 10 VEGFR Inhibitor (Pan) 31 Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).
Carotuximab TRC105|TRC-105 TGFBR inhibitor (pan) 2 Carotuximab (TRC105) is a monoclonal antibody that binds to endoglin, a TGF beta-1 accessory receptor highly expressed on tumor vessel endothelial cells, blocking signaling essential for angiogenesis and potentially decreasing proliferation of tumor cells (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown renal cell carcinoma no benefit Bevacizumab + Carotuximab Clinical Study Actionable In a clinical study, the addition of TRC105 to Avastin (bevacizumab) treatment in renal cell carcinoma patients did not result in improved progression free survival (2.8 mo vs 4.6 mo) when compared to Avastin (bevacizumab) alone (PMID: 28832978). 28832978
Clinical Trial Phase Therapies Title Recruitment Status
NCT02354612 Phase Ib/II Axitinib + Carotuximab Carotuximab + Pazopanib Capecitabine + Carotuximab Carotuximab Bevacizumab + Carotuximab An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy Enrolling by invitation
NCT01727089 Phase II Bevacizumab Bevacizumab + Carotuximab Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer Completed
NCT01806064 Phase I Bevacizumab + Carotuximab A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma Active, not recruiting
NCT02664961 Phase II Bevacizumab + Carotuximab Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) Terminated